Form 8-K - Current report:
SEC Accession No. 0001193125-24-272860
Filing Date
2024-12-09
Accepted
2024-12-09 07:01:29
Documents
18
Period of Report
2024-12-07
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d903914d8k.htm   iXBRL 8-K 42437
2 EX-99.1 d903914dex991.htm EX-99.1 19610
3 EX-99.2 d903914dex992.htm EX-99.2 19830
7 GRAPHIC g903914g1209043823599.jpg GRAPHIC 2937
8 GRAPHIC g903914g1209043854748.jpg GRAPHIC 2937
9 GRAPHIC g903914g1209043915979.jpg GRAPHIC 2937
  Complete submission text file 0001193125-24-272860.txt   231738

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA beam-20241207.xsd EX-101.SCH 2835
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE beam-20241207_lab.xml EX-101.LAB 17235
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE beam-20241207_pre.xml EX-101.PRE 10802
20 EXTRACTED XBRL INSTANCE DOCUMENT d903914d8k_htm.xml XML 3494
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39208 | Film No.: 241533830
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)